|
Std ID |
Description (Standard Title) |
|
GB/T 14233.2-2005
|
Test methods for infusion, transfusion, injection equipment for medical use -- Part 2: Biological test methods
|
|
GB/T 18458.3-2005
|
Part 3 of the switch to infusion: a one-time use dark infusion
|
|
GB/T 1962.1-2001
|
Conical fittings with a 6% (Luer) taper for syringes needles and certain other medical equipment -- Part 1: General requirement
|
|
GB/T 1962.2-2001
|
Conical fittings with a 6% (Luer) taper for syringes, needles and certain other medical equipment -- Part 2: Lock fittings
|
|
GB/T 14233.1-1998
|
Infusion, transfusion, injection equipment for medical use--Part 1: Chemical analysis methods
|
|
GB/T 10160-1995
|
Test methods of locking force and opening force for medical use forceps
|
|
GB/T 14233.1-1993
|
Infusion, transfusion, injection equipment for medical use--Part 1: Chemical analysis methods
|
|
GB/T 14233.2-1993
|
Test methods for infusion, transfusion, injection equipment for medical use. Part 2: Biological test methods
|
|
GB/T 12256-1990
|
Test method for stiffness of hypodermic needle tubing
|
|
GB/T 10162-1988
|
Method of determination for pulling force of clamping of medical forceps
|
|
GB/T 4506-1984
|
Method for the test of sharpness and strength of needles tips
|
|
GB/T 17827-1999
|
Guidelines for radiotherapy treatment rooms design
|
|
GB/T 21666-2025
|
Absorbent incontinence aids for urine and/or faeces - General guidelines on evaluation
|
|
GB/T 45214-2025
|
Data quality evaluation method of human whole genome sequencing
|
|
GB/T 16886.17-2025
|
Biological evaluation of medical devices - Part 17: Toxicological risk assessment of medical device constituents
|
|
GB/T 44138-2024
|
Cardiovascular implants - Cardiovascular absorbable implants
|
|
GB/T 16886.10-2024
|
Biological evaluation of medical devices - Part 10: Tests for skin sensitization
|
|
GB/T 42216.4-2024
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue - Part 4: In situ detection technique
|
|
GB/T 44353.1-2024
|
Medical devices utilizing animal tissues and their derivatives - Part 1: Application of risk management
|
|
GB/T 44353.2-2024
|
Medical devices utilizing animal tissues and their derivatives - Part 2: Controls on sourcing, collection and handling
|
|
GB/T 44418-2024
|
Assistive products - Guidelines on cognitive accessibility - Daily time management
|
|
GB/T 42080.3-2024
|
DNA Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for frozen tissue - Part 3: Isolated DNA
|
|
GB/T 44467-2024
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for saliva - Isolated human DNA
|
|
GB/T 44585.1-2024
|
Application of risk management for medical device connecting IT-network - Part 1: Safety, effectiveness and security in the implementation and use of connected medical devices or connected health software
|
|
GB/T 44586.1-2024
|
In vitro diagnostic medical devices - Multiplex molecular testing for nucleic acids - Part 1: Terminology and general requirements for nucleic acid quality evaluation
|
|
GB/T 44665-2024
|
General requirements for upper and lower limb motor function rehabilitation equipment with assessment and training
|
|
GB/T 44671-2024
|
Basic semen examination - Specification and test methods
|
|
GB/T 44672-2024
|
In vitro diagnostic medical devices - Requirements for international harmonisation protocols establishing metrological traceability of values assigned to calibrators and human samples
|
|
GB/T 44827-2024
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes in metabolomics in urine, venous blood serum and plasma
|
|
GB/T 14191.3-2023
|
Prosthetics and orthotics - Vocabulary - Part 3: Terms relating to orthoses
|
|
GB/T 42818.1-2023
|
Cognitive accessibility - Part 1: General guidelines
|
|
GB/T 42984.1-2023
|
Health software - Part 1: General requirements for product safety
|
|
GB/T 16886.12-2023
|
Biological evaluation of medical devices - Part 12: Sample preparation and reference materials
|
|
GB/T 16886.23-2023
|
Biological evaluation of medical devices - Part 23: Tests for irritation
|
|
GB/T 43278-2023
|
Medical laboratories - Application of risk management to medical laboratories
|
|
GB/T 43279.1-2023
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for venous whole blood - Part 1: Isolated cellular RNA
|
|
GB/T 43279.2-2023
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for venous whole blood - Part 2: Isolated genomic DNA
|
|
GB/T 43279.3-2023
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for venous whole blood - Part 3: Isolated circulating cell free DNA from plasma
|
|
GB/T 16886.1-2022
|
Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
|
|
GB/T 16886.4-2022
|
Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood
|
|
GB/T 16886.6-2022
|
Biological evaluation of medical devices - Part 6: Tests for local effects after implantation
|
|
GB/T 41522-2022
|
Method of DNA microarray for detection of three canine viruses
|
|
GB/T 21919-2022
|
Laboratory medicine - Requirements for the competence of calibration laboratories using reference measurement procedures
|
|
GB/T 40887.2-2022
|
Wheelchair containment and occupant retention systems for accessible transport vehicles designed for use by both sitting and standing passengers - Part 2: Systems for forward-facing wheelchair seated passengers
|
|
GB/T 41696-2022
|
Classification and general technical requirements of lower limb rehabilitation training devices
|
|
GB/T 41697-2022
|
Assistive products for persons with disability - General requirements and test methods
|
|
GB/T 41840-2022
|
Lower limb orthoses components - Polyurethane elastic ankle
|
|
GB/T 41843-2022
|
Assessment of rehabilitation set for classification of functioning, disability and health
|
|
GB/T 42060-2022
|
Medical laboratories - Requirements for collection, transport, receipt, and handling of samples
|
|
GB/T 42061-2022
|
Medical devices - Quality management systems - Requirements for regulatory purposes
|
|
GB/T 42062-2022
|
Medical devices - Application of risk management to medical devices
|
|
GB/T 16886.15-2022
|
Biological evaluation of medical devices - Part 15: Identification and quantification of degradation products from metals and alloys
|
|
GB/T 16886.18-2022
|
Biological evaluation of medical devices - Part 18: Chemical characterization of medical device materials within a risk management process
|
|
GB/T 16886.19-2022
|
Biological evaluation of medical devices - Part 19: Physico-chemical, morphological and topographical characterization of materials
|
|
GB/T 16886.9-2022
|
Biological evaluation of medical devices - Part 9: Framework for identification and quantification of potential degradation products
|
|
GB/T 42080.1-2022
|
RNA Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for frozen tissue - Part 1: Isolated RNA
|
|
GB/T 42080.2-2022
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for frozen tissue - Part 2: Isolated proteins
|
|
GB/T 42216.1-2022
|
RNA Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for formalin-fixed and paraffin-embedded(FFPE) tissue - Part 1: Isolated RNA
|
|
GB/T 42216.2-2022
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for formalin-fixed and paraffin-embedded(FFPE) tissue - Part 2: Isolated proteins
|
|
GB/T 42216.3-2022
|
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue - Part 3: Isolated DNA
|
|
GB/T 42218-2022
|
Clinical laboratory medicine - In vitro diagnostic medical devices - Validation of user quality control procedures by the manufacturer
|
|
GB/T 19702-2021
|
In vitro diagnostic medical devices - Measurement of quantities in samples of biological origin - Requirements for content and presentation of reference measurement procedures
|
|
GB/T 39889-2021
|
Braille writing board
|
|
GB/T 22576.2-2021
|
Medical laboratories - Requirements for quality and competence - Part 2: Requirements in the field of clinical hematological examination
|
|
GB/T 22576.3-2021
|
Medical laboratories - Requirements for quality and competence - Part 3: Requirements in the field of urine examination
|
|
GB/T 22576.4-2021
|
Medical laboratories - Requirements for quality and competence - Part 4: Requirements in the field of clinical chemistry examination
|
|
GB/T 22576.5-2021
|
Medical laboratories - Requirements for quality and competence - Part 5: Requirements in the field of clinical immunology examination
|
|
GB/T 22576.6-2021
|
Medical laboratories - Requirements for quality and competence - Part 6: Requirements in the field of clinical microbiological examination
|
|
GB/T 22576.7-2021
|
Medical laboratories - Requirements for quality and competence - Part 7: Requirements in the field of transfusion medicine
|
|
GB/T 16886.11-2021
|
Biological evaluation of medical devices - Part 11: Tests for systemic toxicity
|
|
GB/T 16886.16-2021
|
Biological evaluation of medical devices - Part 16: Toxicokinetic study design for degradation products and leachables
|
|
GB/T 40887.1-2021
|
Wheelchair containment and occupant retention systems for accessible transport vehicles designed for use by both sitting and standing passengers - Part 1: Systems for rearward-facing wheelchair seated passengers
|
|
GB/T 40888-2021
|
Aids for ostomy and incontinence - Irrigation sets - Requirements and test methods
|
|
GB/T 14191.4-2021
|
Prosthetics and orthotics - Vocabulary - Part 4: Terms relating to limb amputation
|
|
GB/T 39367.1-2020
|
In vitro diagnostic test systems. Qualitative nucleic acid-based in vitro examination procedures for detection and identification of microbial pathogens - Part 1: General requirements, terms and definitions
|
|
GB/T 19703-2020
|
(In Vitro Diagnostic Medical Devices Measurement of Biological Source Samples Requirements for certified reference materials and supporting document content)
|
|
GB/T 29790-2020
|
(Instant inspection quality and ability requirements)
|
|
GB/T 16886.3-2019
|
Biological evaluation of medical devices -- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
|
|
GB/T 37908-2019
|
General analysis regulation of the label-free protein microarray based on imaging ellipsometry
|
|
GB/T 35029-2018
|
Method based the microarray for mutation detection of hereditary hearing loss
|
|
GB/T 36136-2018
|
General requirements of DNA array-based M. tuberculosis drug resistance detection
|
|
GB/T 22576.1-2018
|
Medical laboratories -- Requirements for quality and competence -- Part 1: General requirements
|
|
GB/T 33752-2017
|
Aldehyde slide for microarrays
|
|
GB/T 33805-2017
|
Technical requirement of laser confocal biochip scanner
|
|
GB/T 33806-2017
|
Technical requirement of area fluorescent imaging microarray scanner
|
|
GB/T 16886.12-2017
|
Biological evaluation of medical devices -- Part 12: Sample preparation and reference materials
|
|
GB/T 35533-2017
|
General technical requirement for chromosomal abnormality detection microarray
|
|
GB/T 16886.13-2017
|
Biological evaluation of medical devices -- Part 13: Identification and quantification of degradation products from polymeric medical devices
|
|
GB/T 16886.5-2017
|
Biological evaluation of medical devices -- Part 5: Tests for in vitro cytotoxicity
|
|
GB/T 16886.9-2017
|
Biological evaluation of medical devices -- Part 9: Framework for identification and quantification of potential degradation products
|
|
GB/T 16886.10-2017
|
Biological evaluation of medical devices -- Part 10: Tests for irritation and skin sensitization
|
|
GB/T 16886.6-2015
|
Biological evaluation of medical devices -- Part 6: Tests for local effects after implantation
|
|
GB/T 16886.20-2015
|
Biological evaluation of medical devices -- Part 20: Principles and methods for immunotoxicology testing of medical devices
|
|
GB/T 16886.7-2015
|
Biological evaluation of medical devices -- Part 7: Ethylene oxide sterilization residuals
|
|
GB/T 16886.16-2013
|
Biological evaluation of medical devices -- Part 16: Toxicokinetic study design for degradation products and leachables
|
|
GB/T 29790-2013
|
Point-of-care testing (POCT) -- Requirements for quality and competence
|
|
GB/T 29888-2013
|
General requirements of DNA array-based mycobacteria identification
|
|
GB/T 29889-2013
|
DNA microarray for disease susceptibility DNA polymorphisms
|
|
GB/T 16886.1-2011
|
Biological evaluation of medical devices -- Part 1: Evaluation and testing within a risk management process
|
|
GB/T 16886.11-2011
|
Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity
|